RGT-075 is under clinical development by Qilu Regor Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RGT-075’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RGT-075 overview

RGT-075 is under development for the treatment of type 2 diabetes. It acts by targeting glucagon like peptide 1 receptor (GLP1R). It is administered through oral route. The drug candidate is being developed based on CARD (Computer Accelerated Rational Discovery) platform.

Qilu Regor Therapeutics overview

Regor Pharmaceuticals Inc (Regor) is a biotechnology company that discovers and develops medicines for the treatment of cancer, immune disorders and metabolic diseases. Regor is headquartered in Boston, Massachusetts, the US.

For a complete picture of RGT-075’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.